{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066440","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.819005+00:00","generated_at":"2026-05-22T05:16:40.052850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ALX Oncology Reports Q1 2025 Financial Results, Updates on Evorpacept and ALX2004 Pipeline","bullets":["Reported Q1 2025 net loss of $30.8M ($0.58 per share) compared to $35.6M in Q1 2024; cash runway extended into Q4 2026 with $107.0M in cash.","Received IND clearance from FDA for ALX2004, a novel EGFR-targeted ADC; Phase 1 initiation expected mid-2025 with initial safety data in 1H 2026.","Will not pursue U.S. registrational path for evorpacept in gastric cancer after FDA feedback that accelerated approval not feasible due to ENHERTU®.","Discontinued evorpacept in combination with PADCEV® in urothelial cancer due to lack of improved efficacy in ASPEN-07 trial.","Expect to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies mid-2025, with data milestones in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066440","json":"https://secwatch.observer/filing/0000950170-25-066440.json","markdown":"https://secwatch.observer/filing/0000950170-25-066440.md","text":"https://secwatch.observer/filing/0000950170-25-066440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025066440/0000950170-25-066440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025066440/alxo-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-22T05:16:40.052850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}